Teva Pharmaceutical Industries (NYSE:TEVA) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Teva Pharmaceutical Industries (NYSE:TEVA) had its price objective upped by analysts at JPMorgan Chase & Co. from $35.00 to $40.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price indicates a potential upside of 14.18% from the stock’s current price.

TEVA has been the subject of a number of other research reports. UBS Group increased their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday. Bank of America increased their price objective on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, April 9th. Scotiabank increased their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a research note on Thursday, January 29th. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Monday, April 20th. Finally, Truist Financial increased their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $41.56.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA traded down $0.35 during trading hours on Thursday, hitting $35.03. 16,089,044 shares of the company traded hands, compared to its average volume of 8,324,032. The stock has a market capitalization of $40.28 billion, a price-to-earnings ratio of 29.19, a P/E/G ratio of 2.75 and a beta of 0.76. Teva Pharmaceutical Industries has a twelve month low of $14.99 and a twelve month high of $37.35. The firm has a 50-day moving average of $31.14 and a 200 day moving average of $29.29. The company has a current ratio of 1.04, a quick ratio of 0.80 and a debt-to-equity ratio of 1.89.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. The firm had revenue of $3.98 billion during the quarter. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. On average, analysts forecast that Teva Pharmaceutical Industries will post 2.6 EPS for the current year.

Insiders Place Their Bets

In other news, insider Brian Savage sold 1,127 shares of the company’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $31.67, for a total value of $35,692.09. Following the sale, the insider owned 10,914 shares of the company’s stock, valued at approximately $345,646.38. This represents a 9.36% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Placid Jover sold 14,150 shares of the company’s stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $31.67, for a total transaction of $448,130.50. Following the completion of the sale, the insider directly owned 6,774 shares in the company, valued at approximately $214,532.58. The trade was a 67.63% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 920,901 shares of company stock worth $30,056,789 in the last quarter. 0.54% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Several large investors have recently made changes to their positions in the company. Global Retirement Partners LLC grew its holdings in shares of Teva Pharmaceutical Industries by 27.3% in the 4th quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock worth $42,000 after purchasing an additional 292 shares during the last quarter. Captrust Financial Advisors grew its holdings in Teva Pharmaceutical Industries by 2.1% during the 4th quarter. Captrust Financial Advisors now owns 14,715 shares of the company’s stock worth $459,000 after acquiring an additional 302 shares during the last quarter. Banque Cantonale Vaudoise grew its holdings in Teva Pharmaceutical Industries by 6.3% during the 4th quarter. Banque Cantonale Vaudoise now owns 5,133 shares of the company’s stock worth $160,000 after acquiring an additional 306 shares during the last quarter. Ethic Inc. grew its holdings in Teva Pharmaceutical Industries by 1.8% during the 4th quarter. Ethic Inc. now owns 18,127 shares of the company’s stock worth $566,000 after acquiring an additional 325 shares during the last quarter. Finally, Allworth Financial LP grew its holdings in Teva Pharmaceutical Industries by 53.8% during the 4th quarter. Allworth Financial LP now owns 941 shares of the company’s stock worth $29,000 after acquiring an additional 329 shares during the last quarter. Institutional investors own 54.05% of the company’s stock.

Trending Headlines about Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Q1 results beat estimates: Teva reported EPS of $0.53 and revenue of ~$4.0B, ahead of consensus, driven by branded medicines (Austedo, Ajovy, Uzedy). This strengthens the growth narrative. Reuters: Teva beats Q1 profit estimates
• Positive Sentiment: Analyst upgrades and higher price targets: UBS raised its target to $42 (buy), Truist raised its target to $45 (buy) and Piper Sandler reaffirmed overweight at $42 — signalling institutional optimism and upside vs. the current price. Benzinga: Analyst coverage TickerReport: Truist upgrade
• Positive Sentiment: Strategic M&A: Teva agreed to acquire Emalex (ecopipam), a late‑stage, NDA‑ready Tourette’s therapy — a bolt‑on that supports the pivot toward differentiated, branded growth. GlobeNewswire: Emalex acquisition
• Neutral Sentiment: Sustainability and financing signals: Teva published its 2025 Healthy Future Report and said it met all sustainability‑linked bond targets; separately, a Blackstone financing has drawn attention — both supportive for long‑term credit/ESG positioning but unlikely to move near-term earnings. GlobeNewswire: 2025 Healthy Future Report
• Neutral Sentiment: Market activity: Unusually large options and equity volume were reported around the earnings/transaction news, indicating elevated trading and positioning that can amplify intraday moves. Market activity reports
• Negative Sentiment: Generics weakness and headwinds: Management noted weaker generics revenue (including lenalidomide capsules), which tempers margin outlook and keeps some execution risk on cost or pricing trends. GlobeNewswire: Q1 results and segment notes
• Negative Sentiment: Profit‑taking after a large rally: The stock had a sharp multi‑day run (double‑digit gains recently). Today’s dip appears to reflect short‑term profit‑taking and valuation reassessment even as fundamentals improve. Yahoo Finance: Valuation after earnings

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.